PTGX
Protagonist Therapeutics Inc
NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY
$103.50
-5.26% today
Updated 2026-06-05
Market cap
$6.10B
P/E ratio
—
P/S ratio
85.51x
EPS (TTM)
$-1.81
Dividend yield
—
52W range
$49 – $108
Volume
0.6M
WallStSmart proprietary scores
38
out of 100
Grade: D
Sell
Investment rating
10.0
Growth
A+8.5
Quality
A2.0
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
6.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$115.21
+11.31%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 6.08 — safe zone
+ Revenue growth 99.00% QoQ
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at -154.90%
- Negative free cash flow $-49.16M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $26.58M | $60.00M | $434.43M | $46.02M | $74.06M | $0.5B |
| Net income | $-123.41M | $-78.95M | $275.19M | $-130.15M | $3.78M | — |
| EPS | — | — | — | — | $-1.81 | $4.20 |
| Free cash flow | $-108.93M | $-70.84M | $182.80M | $56.08M | $-49.16M | — |
| Profit margin | -464.29% | -131.59% | 63.34% | -282.83% | -154.90% | — |
Peer comparison
Smart narrative
Protagonist Therapeutics Inc trades at $103.50. Our Smart Value Score of 38/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 6.08, it sits in the safe zone. TTM revenue stands at $74.06M. with profit margins at -154.90%.
Frequently asked questions
What is Protagonist Therapeutics Inc's stock price?
Protagonist Therapeutics Inc (PTGX) trades at $103.50, on a P/S of 85.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Protagonist Therapeutics Inc overvalued?
Protagonist Therapeutics Inc carries a Smart Value Score of 38/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Protagonist Therapeutics Inc (PTGX)?
The 12-month analyst consensus target is $115.21, about 11.3% above the current $103.50. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of PTGX by 2030?
Our research-backed model puts the 2030 base case at $508.08, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Protagonist Therapeutics Inc's revenue?
Protagonist Therapeutics Inc's trailing twelve-month revenue is $74.06M, and our model projects it reaching about $620.00M by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Protagonist Therapeutics Inc's Altman Z-Score is 6.08, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio85.51x
ROE-17.50%
Beta1.88
50D MA$101.62
200D MA$84.20
Shares out0.06B
Float0.05B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—